We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Rabbit Poxvirus Kills Brain Cancer Cells

By Biotechdaily staff writers
Posted on 07 Dec 2005
Researchers have used myxoma virus, a poxvirus that causes fatal myxomatosis in rabbits, to kill human brain cancer cells both in tissue culture and after transplantation into mice.

After earlier studies showed that the mxyoma virus could survive in a variety of human tumor cells in culture, investigators at the University of Western Ontario (London, Canada) and the University of Calgary (Alberta, Canada) performed a series of experiments designed to test its effectiveness against a human malignant brain cancer (glioma).

They reported in the November 1, 2005, issue of Cancer Research that when used to infect eight different glioma cell lines growing in tissue culture, the myxoma virus reproduced in seven of the lines and killed the cells.

In another series of experiments, a mouse model was created by transplantation of human glioma cells into the animals' brains. More...
The growing tumors were then treated by being inoculated with either live myxoma virus or with myxoma virus that had been inactivated by exposure to ultraviolet (UV) light. All the animals treated with UV inactivated virus were dead after about 50 days, while 92% of those treated with the live virus were still living when the experiment was ended after 130 days. The virus itself had no apparent toxic effects on the mice.
"Those animals continued to show a selective and long-lived myxoma virus infection in the tumors themselves but that infection did not spread and harm the animal,” explained senior author Dr. Peter Forsyth, professor of oncology, biochemistry, and molecular biology at the University of Calgary. "This and other factors suggest that myxoma virus warrants further investigation as a potential treatment for malignant brain tumors in people.”




Related Links:
University of Western Ontario
University of Calgary

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.